Vitamin D doesn't confer any cardiovascular disease protection: JAMA
By - Dr. Kamal Kant Kohli Kohli
Published On 2019-06-21 14:40 GMT | Update On 2021-08-11 10:22 GMT
Vitamin D doesn't provide cardiovascular protection and reduce CVD risk, finds a meta analysis.
The researchers conducted a meta-analysis of randomized clinical trials that tested the association of vitamin D supplementation with reduced CVD events and all-cause mortality.They have found in this updated meta-analysis that vitamin D supplementation was not associated with reduced major adverse cardiovascular events.The study has been published in JAMA Cardiology.
Vitamin D is a hormone synthesized in the skin in the presence of sunlight. Like other hormones, vitamin D plays a role in a wide range of processes in the body.
Oral intake from natural and fortified foodstuffs, as well as from supplementation, adds to vitamin D levels in the individual. Like other hormones, vitamin D plays a role in a wide range of processes in the body. Sufficient vitamin D levels are important not only for a healthy skeleton but also for a healthy immune system.
Some observational studies have suggested an association between low blood levels of vitamin D and an increased risk of cardiovascular disease events.
The researchers searched literature through PubMed, the Cochrane Library, and Embase was completed by 2 reviewers from each database's inception to December 15, 2018 and included randomized clinical trials that reported the effect of long-term (≥1 year) vitamin D supplementation on CVD events and all-cause mortality. Studies that did not include cardiovascular outcomes were excluded.
Major adverse cardiovascular events was the primary outcome, and rates of myocardial infarction, stroke or cerebrovascular accident, CVD mortality, and all-cause mortality were the secondary end points.
The researchers went through data and conducted a meta-analysis by combining the results of 21 randomized clinical trials. They looked into data of about 83,000 patients to , of whom 41 669 received vitamin D and 41 622 received placebos). The mean (SD) age of trial participants was 65.8 (8.4) years; 61 943 (74.4%) were female. Only 4 trials had prespecified CVD as a primary end point. Vitamin D supplementation compared with placebo was not associated with reduced major adverse cardiovascular events nor the secondary end points of myocardial infarction , stroke, CVD mortality , or all-cause mortality. Results were generally consistent by sex, baseline 25-hydroxyvitamin D level, vitamin D dosage, formulation (daily vs bolus dosing), and presence or absence of concurrent calcium administration.
The researchers concluded that In this updated meta-analysis, vitamin D supplementation was not associated with reduced major adverse cardiovascular events, individual CVD end points (myocardial infarction, stroke, CVD mortality), or all-cause mortality. The findings suggest that vitamin D supplementation does not confer cardiovascular protection and is not indicated for this purpose.
The results were similar between different doses of vitamin D and for men and women. A limitation of the study is that the definition of major adverse cardiovascular events varied between the clinical trials.
For further reference log on to:
doi:10.1001/jamacardio.2019.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd